Looking for ideas before Christmas? These 2 ASX shares stand out to me

Two ASX shares at opposite ends of the market are catching my attention as the year draws to a close.

Key points
  • Despite previous challenges, CSL offers potential growth and stability with improving plasma collections and strong demand for its healthcare products.
  • Known for its notable dividend yield of approximately 11%, Accent presents an attractive option for income-focused investors keen on retail sector resilience.
  • Both CSL and Accent are compelling options for those seeking either long-term growth or immediate income as the year draws to a close.

As Christmas approaches, plenty of investors start thinking about where to put fresh money to work before the new year. I am no different. With markets still a bit choppy and sentiment mixed across sectors, I have been focusing on quality businesses where the risk-reward balance looks attractive heading into 2026.

Two ASX shares are standing out to me right now, despite sitting at opposite ends of the market. For different reasons, both are worth a closer look.

ecommerce asx shares represented by santa doing online shopping on laptop

Image source: Getty Images

CSL Ltd (ASX: CSL)

The CSL share price has had a tough run over the past year and is trading around $175, well below the levels investors had become used to. Softer profit guidance, higher costs, and a slower-than-expected recovery in plasma collections weighed on sentiment, and the market did not take kindly to that.

That being said, the long-term story has not broken. Plasma collections have been improving, Seqirus continues to perform solidly, and CSL Vifor is starting to settle after a challenging integration period. Cost discipline is also coming into focus, which is usually the first step toward margin recovery.

Several brokers continue to describe CSL as oversold, with price targets well above current levels. For a global healthcare leader with a long track record of growth, a strong balance sheet, and solid demand for immunoglobulin and vaccines, the current share price is starting to look far more appealing than it did a year ago.

If CSL can show steadier execution across FY26, the share price could start to find support.

Accent Group Ltd (ASX: AX1)

At the other end of the spectrum sits Accent, with its share price trading around 90 cents. The footwear retailer owns well-known brands such as Platypus, Hype DC and The Athlete's Foot, and it has built a strong omnichannel business across Australia and New Zealand.

What really stands out here is income. Accent paid 10 cents per share in fully franked dividends over the past year, which puts the trailing yield at roughly 11% at current prices. That is a big number for an ASX 200 stock.

While retail always carries some risk, Accent has performed better than many of its peers, with resilient margins and solid digital sales. Management continues to invest in store rollouts and owned brands, which support earnings over time.

For income-focused investors who are comfortable with some volatility, Accent offers a level of yield that is hard to ignore.

Foolish Takeaway

CSL and Accent Group are very different businesses, but both stand out to me as we head into Christmas. CSL offers quality and long-term growth at a much lower price than usual, while Accent provides immediate income at an attractive yield.

For investors looking to add ideas before the year ends, these two ASX shares are well worth having on the watchlist.

Motley Fool contributor Aaron Teboneras has positions in CSL. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has positions in and has recommended CSL. The Motley Fool Australia has recommended Accent Group and CSL. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

A female scientist in a laboratory setting using a tablet to review data, with a male scientist working in the background.
Healthcare Shares

ResMed vs Fisher & Paykel Healthcare: Which is better value?

How do ResMed and Fisher & Paykel compare on value, income, and share price momentum? Here’s my verdict on which…

Read more »

Happy doctor using her laptop.
Healthcare Shares

CSL unveils exclusive Alentis deal to advance rare disease treatments

CSL unveils a major partnership for rare disease drug development, enhancing its global nephrology strategy.

Read more »

Doctor sees virtual images of the patient's x-rays on a blue background.
Healthcare Shares

Could this ASX biotech really jump more than 80% in value?

This company's new technology has one broker impressed.

Read more »

Teamwork, planning and meeting with doctors and laptop for medical, review and healthcare. Medicine, technology and internet with group of people for collaboration, diversity and support in hospital
Healthcare Shares

CSL vs Pro Medicus: Which ASX healthcare share is better?

Both CSL and Pro Medicus have faced recent challenges but have enviable long-term track records. Here's which one I'd buy…

Read more »

Scientists working in the laboratory and examining results.
Healthcare Shares

This ASX biotech could rise almost 50%, Morgans says

Turning science into contracts could unlock value for this company.

Read more »

Doctor with stethoscope using a tablet in a hospital.
Healthcare Shares

Telix Pharmaceuticals wins FDA Fast Track for BiPASS prostate cancer imaging

Telix Pharmaceuticals shares are in the spotlight after the FDA granted Fast Track for its BiPASS pre-biopsy prostate cancer imaging…

Read more »

Three scientists looking at a laptop in a lab.
Healthcare Shares

What would it take for CSL shares to return to $250?

The shares have already recovered strongly, so I wanted to see whether $250 is realistic.

Read more »

Doctor with stethoscope typing on her computer.
Healthcare Shares

Is the ResMed share price a cheap buy?

I look at what the next few years of earnings growth could mean for today’s valuation.

Read more »